These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 24077631)
1. In vitro functional characterization of 37 CYP2C9 allelic isoforms found in Chinese Han population. Dai DP; Wang YH; Wang SH; Geng PW; Hu LM; Hu GX; Cai JP Acta Pharmacol Sin; 2013 Nov; 34(11):1449-56. PubMed ID: 24077631 [TBL] [Abstract][Full Text] [Related]
2. In vitro metabolism of phenytoin in 36 CYP2C9 variants found in the Chinese population. Chen LG; Wang Z; Zhu Y; Xiong JH; Sun LR; Dai DP; Cai JP; Hu GX Chem Biol Interact; 2016 Jun; 253():93-9. PubMed ID: 27163851 [TBL] [Abstract][Full Text] [Related]
3. In vitro assessment of 36 CYP2C9 allelic isoforms found in the Chinese population on the metabolism of glimepiride. Dai DP; Wang SH; Geng PW; Hu GX; Cai JP Basic Clin Pharmacol Toxicol; 2014 Apr; 114(4):305-10. PubMed ID: 24118918 [TBL] [Abstract][Full Text] [Related]
4. In vitro assessment of 39 CYP2C9 variants found in the Chinese population on the metabolism of the model substrate fluoxetine and a summary of their effects on other substrates. Ji Y; Chen S; Zhao L; Pan P; Wang L; Cai J; Dai D; Hu G; Cai JP; Huang H J Clin Pharm Ther; 2015 Jun; 40(3):320-7. PubMed ID: 25884291 [TBL] [Abstract][Full Text] [Related]
5. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Sullivan-Klose TH; Ghanayem BI; Bell DA; Zhang ZY; Kaminsky LS; Shenfield GM; Miners JO; Birkett DJ; Goldstein JA Pharmacogenetics; 1996 Aug; 6(4):341-9. PubMed ID: 8873220 [TBL] [Abstract][Full Text] [Related]
6. Effect of 36 CYP2C9 variants found in the Chinese population on losartan metabolism in vitro. Wang YH; Pan PP; Dai DP; Wang SH; Geng PW; Cai JP; Hu GX Xenobiotica; 2014 Mar; 44(3):270-5. PubMed ID: 23844998 [TBL] [Abstract][Full Text] [Related]
7. Catalytic activities of human cytochrome P450 2C9*1, 2C9*3 and 2C9*13. Guo Y; Wang Y; Si D; Fawcett PJ; Zhong D; Zhou H Xenobiotica; 2005 Sep; 35(9):853-61. PubMed ID: 16308280 [TBL] [Abstract][Full Text] [Related]
8. Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes. Yamazaki H; Inoue K; Shimada T Xenobiotica; 1998 Feb; 28(2):103-15. PubMed ID: 9522436 [TBL] [Abstract][Full Text] [Related]
9. Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians. DeLozier TC; Lee SC; Coulter SJ; Goh BC; Goldstein JA J Pharmacol Exp Ther; 2005 Dec; 315(3):1085-90. PubMed ID: 16099926 [TBL] [Abstract][Full Text] [Related]
10. Cloning of cytochrome P-450 2C9 cDNA from human liver and its expression in CHL cells. Zhu GJ; Yu YN; Li X; Qian YL World J Gastroenterol; 2002 Apr; 8(2):318-22. PubMed ID: 11925616 [TBL] [Abstract][Full Text] [Related]
11. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations. Inoue K; Yamazaki H; Imiya K; Akasaka S; Guengerich FP; Shimada T Pharmacogenetics; 1997 Apr; 7(2):103-13. PubMed ID: 9170147 [TBL] [Abstract][Full Text] [Related]
12. Effect of CYP2C9 genetic polymorphism on the metabolism of flurbiprofen in vitro. Wang L; Bao SH; Pan PP; Xia MM; Chen MC; Liang BQ; Dai DP; Cai JP; Hu GX Drug Dev Ind Pharm; 2015; 41(8):1363-7. PubMed ID: 25144335 [TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo characterization of 13 CYP2C9 allelic variants found in Chinese Han population. Hu GX; Pan PP; Wang ZS; Yang LP; Dai DP; Wang SH; Zhu GH; Qiu XJ; Xu T; Luo J; Lian QQ; Ge RS; Cai JP Drug Metab Dispos; 2015 Apr; 43(4):561-9. PubMed ID: 25614704 [TBL] [Abstract][Full Text] [Related]
14. Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populations. Yang JQ; Morin S; Verstuyft C; Fan LA; Zhang Y; Xu CD; Barbu V; Funck-Brentano C; Jaillon P; Becquemont L Fundam Clin Pharmacol; 2003 Jun; 17(3):373-6. PubMed ID: 12803577 [TBL] [Abstract][Full Text] [Related]
15. Discovery of new potentially defective alleles of human CYP2C9. Blaisdell J; Jorge-Nebert LF; Coulter S; Ferguson SS; Lee SJ; Chanas B; Xi T; Mohrenweiser H; Ghanayem B; Goldstein JA Pharmacogenetics; 2004 Aug; 14(8):527-37. PubMed ID: 15284535 [TBL] [Abstract][Full Text] [Related]
16. No major difference in inhibitory susceptibility between CYP2C9.1 and CYP2C9.3. Hanatani T; Fukuda T; Onishi S; Funae Y; Azuma J Eur J Clin Pharmacol; 2003 Jul; 59(3):233-5. PubMed ID: 12756514 [TBL] [Abstract][Full Text] [Related]
17. Distribution of CYP2C9*13 allele in the Chinese Han and the long-range haplotype containing CYP2C9*13 and CYP2C19*2. Si D; Wang J; Zhang Y; Zhong D; Zhou H Biopharm Drug Dispos; 2012 Sep; 33(6):342-5. PubMed ID: 22886551 [TBL] [Abstract][Full Text] [Related]
18. Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. Chang TK; Yu L; Goldstein JA; Waxman DJ Pharmacogenetics; 1997 Jun; 7(3):211-21. PubMed ID: 9241661 [TBL] [Abstract][Full Text] [Related]
19. Functional characterization of 32 CYP2C9 allelic variants. Niinuma Y; Saito T; Takahashi M; Tsukada C; Ito M; Hirasawa N; Hiratsuka M Pharmacogenomics J; 2014 Apr; 14(2):107-14. PubMed ID: 23752738 [TBL] [Abstract][Full Text] [Related]
20. Identification and drug metabolic characterization of four new CYP2C9 variants Zhao FL; Zhang Q; Wang SH; Hong Y; Zhou S; Zhou Q; Geng PW; Luo QF; Yang JF; Chen H; Cai JP; Dai DP Front Pharmacol; 2022; 13():1007268. PubMed ID: 36582532 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]